STUDY OBJECTIVE: To determine the repeatability of measurements of FEV(1) in adults with lung disease due to cystic fibrosis (CF). DESIGN: Single cohort study nested within a randomized controlled trial. SETTING:Adult CF of a university teaching hospital. Subjects were participants in a randomized trial of an experimental mucolytic drug. PATIENTS: Twenty-one adults (mean age, 27.5 +/- 9.2 years [+/- SD]) with CF and mild-to-moderate airflow obstruction (FEV(1) 70 +/- 15% predicted). Patients were in clinically stable condition prior to and during the study. INTERVENTIONS:Repeated FEV(1) measurements were obtained at specific times of the day for 9 consecutive days, for a total of 31 measurements from each subject. Statistical measures of repeatability were calculated. Variation over the course of 1 day and variation from 1 day to the next were examined separately. MEASUREMENTS AND RESULTS: For day-to-day FEV(1) measurements, the within-subject SD was 0.145 L (4.5% of predicted), indicating greater variation compared to values previously established in normal subjects. The coefficient of repeatability indicated that day-to-day measurements could differ by as much as 13% of predicted in the absence of clinical change. For measurements within a single day, variation was not observed to be greater than normal. CONCLUSIONS: In adults with CF, day-to-day variation in FEV(1) measurements is greater than normal and similar to that seen in other obstructive lung diseases. Changes in FEV(1) over time in adults with CF can likely be interpreted using the same criteria that apply to asthma or COPD.
RCT Entities:
STUDY OBJECTIVE: To determine the repeatability of measurements of FEV(1) in adults with lung disease due to cystic fibrosis (CF). DESIGN: Single cohort study nested within a randomized controlled trial. SETTING: Adult CF of a university teaching hospital. Subjects were participants in a randomized trial of an experimental mucolytic drug. PATIENTS: Twenty-one adults (mean age, 27.5 +/- 9.2 years [+/- SD]) with CF and mild-to-moderate airflow obstruction (FEV(1) 70 +/- 15% predicted). Patients were in clinically stable condition prior to and during the study. INTERVENTIONS: Repeated FEV(1) measurements were obtained at specific times of the day for 9 consecutive days, for a total of 31 measurements from each subject. Statistical measures of repeatability were calculated. Variation over the course of 1 day and variation from 1 day to the next were examined separately. MEASUREMENTS AND RESULTS: For day-to-day FEV(1) measurements, the within-subject SD was 0.145 L (4.5% of predicted), indicating greater variation compared to values previously established in normal subjects. The coefficient of repeatability indicated that day-to-day measurements could differ by as much as 13% of predicted in the absence of clinical change. For measurements within a single day, variation was not observed to be greater than normal. CONCLUSIONS: In adults with CF, day-to-day variation in FEV(1) measurements is greater than normal and similar to that seen in other obstructive lung diseases. Changes in FEV(1) over time in adults with CF can likely be interpreted using the same criteria that apply to asthma or COPD.
Authors: Edwin J R van Beek; Catherine Hill; Neil Woodhouse; Stanislao Fichele; Sally Fleming; Bridget Howe; Sandra Bott; Jim M Wild; Christopher J Taylor Journal: Eur Radiol Date: 2006-08-29 Impact factor: 5.315
Authors: David Taylor-Robinson; Margaret Whitehead; Finn Diderichsen; Hanne Vebert Olesen; Tania Pressler; Rosalind L Smyth; Peter Diggle Journal: Thorax Date: 2012-05-03 Impact factor: 9.139
Authors: Andre Yaroshenko; Katharina Hellbach; Ali Önder Yildirim; Thomas M Conlon; Isis Enlil Fernandez; Martin Bech; Astrid Velroyen; Felix G Meinel; Sigrid Auweter; Maximilian Reiser; Oliver Eickelberg; Franz Pfeiffer Journal: Sci Rep Date: 2015-12-01 Impact factor: 4.379
Authors: Courtney M Wheatley; Sarah E Baker; Cori M Daines; Hanna Phan; Marina G Martinez; Wayne J Morgan; Eric M Snyder Journal: Ther Adv Respir Dis Date: 2018 Jan-Dec Impact factor: 4.031